Additionally, in current research, FOXM1 amplification was reported to confer primary resistance of gefitinib in non-small cell lung cancer (NSCLC) and acquired paclitaxel resistance in breast cancer, showing implications in resistance to chemotherapy strongly [24,25]. The gene discussed is FOXM1; the disease is non-small cell lung carcinoma.